Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reslizumab Efficacy and Safety in Eosinophilic Asthma (Study 3081)
NCT01270464Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Feb 2011
- Primary completion
- Sep 2013
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
A Phase 3 trial of reslizumab in eosinophilic asthma (EA), sponsored by Teva Pharmaceutical Industries Ltd.. Started Feb 2011; status: completed.
02
Drugs
reslizumab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on NCT01270464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01270464.